| NKCx Histopathological outcome* within 12 months after cervix cytology in 2024 |
| 211 Östergötland |
| Benign | LSIL | HSIL | AIS | Cancer | Other | PAD missing | Total | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cytologi | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
| Benign sample | 82 | 6.5% | 39 | 3.1% | 19 | 1.5% | 2 | 0.2% | . | . | 2 | 0.2% | 1115 | 88.6% | 1259 | 100.0% |
| ASCUS | 103 | 19.4% | 119 | 22.4% | 58 | 10.9% | 4 | 0.8% | . | . | 1 | 0.2% | 247 | 46.4% | 532 | 100.0% |
| LSIL | 51 | 17.2% | 62 | 20.9% | 38 | 12.8% | . | . | . | . | . | . | 146 | 49.2% | 297 | 100.0% |
| Atypical glandular cells/AGC | . | . | . | . | 1 | 100.0% | . | . | . | . | . | . | . | . | 1 | 100.0% |
| ASC-H | 1 | 11.1% | 1 | 11.1% | 6 | 66.7% | 1 | 11.1% | . | . | . | . | . | . | 9 | 100.0% |
| HSIL | 2 | 5.6% | 1 | 2.8% | 27 | 75.0% | 2 | 5.6% | 1 | 2.8% | 1 | 2.8% | 2 | 5.6% | 36 | 100.0% |
| Squamous cell cancer | . | . | . | . | 1 | 33.3% | . | . | 2 | 66.7% | . | . | . | . | 3 | 100.0% |
| Totalt | 239 | 11.2% | 222 | 10.4% | 150 | 7.0% | 9 | 0.4% | 3 | 0.1% | 4 | 0.2% | 1510 | 70.7% | 2137 | 100.0% |
| NOTE: Histopathological outcome from T83x taken into account. |
| This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad. |
| * Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead. |
| The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'. |
| Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories. |
| Snomed codes in the category Cancer: |
|---|
| M80703 |